First human tests begin for promising new eczema injection
NCT ID NCT06055361
Summary
This early-stage study is testing a new injectable medication called BxC-I17e for adults with moderate-to-severe atopic dermatitis (eczema). Researchers will give 45 participants either the drug or a placebo to check for side effects and see if it helps reduce skin symptoms. The main goal is to determine if the treatment is safe and well-tolerated before larger studies can begin.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arkansas Research Trials
RECRUITINGNorth Little Rock, Arkansas, 72117, United States
Contact
-
DermDox Centers for Dermatology
RECRUITINGCamp Hill, Pennsylvania, 17011, United States
Contact
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Conditions
Explore the condition pages connected to this study.